Clinical Trial

A Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLC

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated July 8, 2024 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study, including phase Ib , phase IIa and phase IIb, aims to evaluate the safety, tolerability, PK profile, efficacy and to determine the RP2D of GH21 capsules combined with Osimertinib mesylate tablets in NSCLC patients with EGFR mutations.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-03-05; most recent amendment 2024-07-04.
Trial Details
NCT Number NCT06306456
Lead Sponsor Suzhou Genhouse Bio Co., Ltd.
Conditions Non-Small Cell Lung Cancer With EGFR Mutation
Enrollment 94 participants
Start Date 2024-03-05
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-07-08